Active	Status	Sponsor type	Region	Phase	Filter
4 Active 1 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Krause, Stefan
TRIANGLE, NCT02858258: ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma	Recruiting	3	870	Europe	R-CHOP/R-DHAP, rituximab, CHOP, DHAP, Ibrutinib (Induction), Imbruvica, ASCT conditioning, THAM or BEAM, Ibrutinib (Maintenance)	Prof. Dr. M. Dreyling (co-chairman), LMU Klinikum	Mantle Cell Lymphoma	05/21	05/26
DaunoDouble, NCT02140242 / 2013-003191-12: Comparison Between Two Dose Levels of Daunorubicin and Between One vs. Two Induction Cycles for Adult Patients With AML	Completed	3	721	Europe, RoW	study part 1 - dose daunorubicin, induction cycles	Technische Universität Dresden, University Hospital Dresden, Masaryk University	Leukemia, Myelocytic, Acute	04/22	04/22
VINCENT, NCT05904106: Venetoclax Plus Azacitidine Versus Intensive Chemotherapy for Fit Patients With Newly Diagnosed NPM1 Mutated AML	Not yet recruiting	2	146	Europe	Venetoclax plus Azacitidine, standard of care chemotherapy plus gemtuzumab ozogamicin	Technische Universität Dresden, University Hospital Heidelberg, AbbVie	Acute Myeloid Leukemia	09/28	09/28
NCT03188874: Clinical AML Registry and Biomaterial Database of the Study Alliance Leukemia (SAL)	Recruiting	N/A	15000	Europe		Technische Universität Dresden	Acute Myeloid Leukemia (AML)	09/30	09/30